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Summary
Background: There is a need to improve therapies for osteoarthritis in horses.
Objectives: To assess the efficacy of equine allogeneic chondrogenic-induced mesenchymal stem cells combined with equine allogeneic plasma as a
novel therapy for osteoarthritis in horses.
Study design: Randomised, double-blinded, placebo-controlled experiment.
Methods: In 12 healthy horses, osteoarthritis was induced in the metacarpophalangeal joint using an osteochondral fragment-groove model. Five
weeks after surgery, horses were randomly assigned to either an intra-articular injection with chondrogenic-induced mesenchymal stem cells + equine
allogeneic plasma (= intervention) or with 0.9% saline solution (= control). From surgery until the study end, horses underwent a weekly joint and
lameness assessment. Synovial fluid was collected for cytology and biomarker analysis before surgery and at Weeks 5, 5 + 1d, 7, 9 and 11. At Week 11,
horses were subjected to euthanasia, and the metacarpophalangeal joints were evaluated macroscopically and histologically.
Results: No serious adverse events or suspected adverse drug reactions occurred during the study. A significant improvement in visual and objective
lameness was seen with the intervention compared with the control. Synovial fluid displayed a significantly higher viscosity and a significantly lower
glycosaminoglycan concentration in the intervention group. Other biomarkers or cytology parameters were not significantly different between the
treatment groups. Significantly less wear lines and synovial hyperaemia were present in the intervention group. The amount of cartilage oligomeric
matrix protein, collagen type II and glycosaminoglycans were significantly higher in the articular cartilage of the intervention group.
Main limitations: This study assessed the short-term effect of the intervention on a limited number of horses, using an osteoarthritis model. This
study also included multiple statistical tests, increasing the risk of type 1 error.
Conclusions: Equine allogeneic chondrogenic-induced mesenchymal stem cells combined with equine allogeneic plasma may be a promising
treatment for osteoarthritis in horses.
The Summary is available in Spanish – see Supporting Information
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Introduction
Osteoarthritis (OA) in horses often results in an early retirement from an
athletic career or pleasure riding [1–3]. Currently, treatment of OA is mainly
focused on addressing the clinical signs [1,3]. The most commonly used
treatments are corticosteroids, nonsteroidal anti-inflammatory drugs,
hyaluronan and polysulfated glycosaminoglycan [2]. However, to date,
none of these treatments halts the disease, let alone reverse it, so none of
the current treatment modalities presents a durable solution for OA [4].
Regenerative medicine represents an interesting alternative for treating
OA, since it has the potential to prevent further cartilage damage and even
reverse the sustained damage [4–7]. Intra-articular use of native
mesenchymal stem cells (MSCs) has shown promising, though modest,
results for enhancing cartilage repair [4–8]. Moreover, the application of
chondrogenic-induced MSCs combined with plasma in horses with OA has
been shown to have a clinical advantage compared with using plasma
alone or native MSCs combined with plasma [7,8]. In those two studies,
allogeneic MSCs (from another animal than the case, but from the same
species) instead of autologous MSCs were used, as allogeneic MSCs allow
‘off-the-shelf’ therapy. However, randomised, double-blinded, placebo-
controlled studies to objectively investigate efficacy of allogeneic MSCs are
currently lacking.
Therefore, the goal of this study was to assess the efficacy of a single
intra-articular injection of equine allogeneic chondrogenic-induced MSCs
combined with equine allogeneic plasma in an experimental model of
metacarpophalangeal (MCP) OA. We hypothesised that this combination
would have a superior effect on OA improvement compared with saline
(0.9%).
Materials and methods
Study design and animals
Twelve healthy warmblood horses, three geldings and nine mares
(median age 8.5 years), were enrolled in this blinded, controlled,
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randomised and blocked study. The horses were free of visual lameness
and presented no radiographic abnormalities of the MCP joints. The
treatment was randomised using Randomizer_2 (2.1.0).xls. The horses
were assigned to either the intervention group (n = 6) or to the control
group (n = 6) per block of 2 horses (ratio 1:1).
Intervention and control product
Intervention product: The intervention consisted of a proprietary
formulation of equine allogeneic chondrogenic-induced MSCs (ciMSCs)
derived from peripheral blood (2 9 106 cells in 1 mL of Dulbecco’s
modified Eagle medium low glucose with 10% of dimethyl sulfoxide)a
combined with equine allogeneic plasma (EAP) (1 mL plasma with
98 9 106 platelets/mL) (Arti-Cell Forte)b . The ciMSCs and EAP were each
stored in separate vials at 80°C until clinical application. Both donor
horses (one for the ciMSCs and one for the EAP) were screened for 32
equine pathogens and collection of their blood was approved by the local
ethics committee (approval number: EC_2012_001). These horses were not
involved further in this study in any way. The IVP was produced according
to Good Manufacturing Practice guidelines (BE/GMP/2015/082 and BE/GMP/
2016/069) with a manufacturing authorisation (1868V) for veterinary
medicinal cell-based products.
Control product: The control product consisted of a sterile saline solution
(0.9% NaCl)c .
OA joint model and exercise programme
Osteoarthritis was surgically induced in the right MCP joint of all horses at
the study start (Week 0) as previously described [9]. Briefly, the joint was
arthroscopically assessed for the presence of pre-existing cartilage lesions.
These lesions were documented but were not an exclusion criterion. In the
right MCP joint, a dorsomedial P1 osteochondral (OC) fragment was
created that remained attached to the dorsal joint capsule and the
fragment bed was debrided with an arthroburr to decrease apposition
between fragment and fracture bed. Next, a horizontal groove in the
cartilage on the dorsal aspect of the medial condyle of the third
metacarpal bone was created using the arthroburr. Skin incisions were
closed and a bandage was applied.
All horses received a single dose of morphine (0.1 mg/kg btw i.v.) and
antibiotics (sodium benzylpenicillin 107 iu i.v.) during surgery. No
medication was administered post-operatively. Horses were box rested for
1 week after surgery, after which they were treadmill exercised for the
remainder of the study period as previously described [9].
Treatment administration
At Week 5, the intervention or control product was administered in the
right MCP joint after sedation with detomidine hydrochloride (i.v., 20 lg/kg
bwt). One vial of ciMSCs and one vial of EAP were thawed and drawn into
one syringe, so a total volume of 2 mL was obtained. The same volume
was used for the control product. Because of the nature of the intervention
and control product (colour difference), this study was blinded by using
separate personnel for clinical and laboratory examinations (investigators)
and for administration of treatments (dispenser). One and the same
investigator performed the clinical scorings throughout the study. Another
investigator performed the histological scoring. For the macroscopic
evaluation of the joint after euthanasia, a consensus score was derived
after reaching an agreement between these two scoring investigators.
Efficacy outcome
Clinical and joint assessment: Horses underwent a daily general clinical
examination and a weekly joint assessment throughout the entire study
period (Fig 1). The joint assessment consisted of an evaluation of local
temperature, joint effusion, pain on palpation, range of motion and
measuring of the joint circumference using a measuring tape. An overview
of the scoring system used for the joint assessment parameters can be
found in Supplementary Item 1.
Lameness examination: A weekly visual and objective lameness
examination was performed during the entire study period. The horses
were examined on a treadmill, during lungeing on a soft surface, and in a
straight line before and after distal forelimb flexion. Lameness was visually
scored using the AAEP lameness scale [10]. The response to flexion was
scored as follows: 0 = no response to flexion, 1 = mild response to flexion,
2 = moderate response to flexion and 3 = severe response to flexion.
Objective evaluation was performed using an inertial sensor-based system
(The Equinosis Q with Lameness Locator software)d [11,12]. A positive
vector sum represented right front limb lameness and a negative one left
front limb lameness. At Weeks 0, 5 and 11, a pressure plate analysis was
performed using a combination of a 2-m pressure plate (RSscan 3D 2 m-
system)e and a force plate (AMTI BP4602070RS-2K)f providing dynamic
calibration of the pressure plate as previously described [13,14]. Symmetry
indices were calculated and expressed as % symmetry (left/right 9 100%).
Radiographic examination: Radiographs of both MCP joints including
lateromedial, dorsopalmar and 45-degree dorsolateral–palmaromedial and
dorsomedial–palmarolateral oblique projections were taken before and the
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Fig 1: A schematic presentation of the adhered time line with an overview of the different procedures performed at each time point.
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day after surgery, and at Weeks 5 and 11. Radiographic changes were
recorded.
Synovial fluid analysis: Synovial fluid samples were collected during
surgery, the day of and after treatment and at Weeks 7, 9 and 11.
Cytological evaluation was performed using a haematology analyser, and
viscosity was assessed using following scoring system: 0 = watery, no
string, 1 = tacky, string <0.5 cm, 2 = string 0.5–4 cm and 3 = string
>4 cm. The following biomarkers were determined using commercial ELISA
kits according to the manufacturers’ instructions: IL-10g, IL-1 receptor
antagonist protein (IRAP)h, PGE2i, MMP-13g, IL-6j, serum amyloid A (SAA)g,
TNF-ah, IFN-ɣh, hyaluronic acid (HA)k, glycosaminoglycans (GAGs)k,l and
TGF-b3j.
Post-mortem examination: After all examinations were performed at
Week 11, all horses were subjected to euthanasia using an i.v. injection
with a combination product containing embutramide (T-61)m.
Gross examination and histology—Both MCP joints were evaluated
macroscopically for cartilage and synovial health according to the
guidelines of the Osteoarthritis Research Society International (OARSI) [14]
as described previously [9]. Cartilage was collected from both MCP joints
from the area adjacent to the created fragment and at the level of the
groove lesion. In addition, joint capsule and synovium were sampled. All
samples were fixed in a 4% formaldehyde solution, embedded in paraffin,
sectioned at 4 lm thickness and stained with haematoxylin and eosin.
Cartilage repair and joint inflammation were evaluated using modified
OARSI histological guidelines [15] as previously described [9]. Moreover,
the presence of ectopic tissue was recorded. Cartilage samples were also
stained with Alcian Blue to assess GAGs content through area %
calculations (see Immunohistochemistry).
Immunohistochemistry—Immunohistochemistry was performed on the
collected tissue samples to evaluate cartilage oligomeric matrix protein
(COMP), collagen type II, Ki67 and caspase 3 expression. Tissue sections
were stained with rabbit polyclonal anti-COMP (ab74524, 1:50)g, anti-
collagen II (ab34712, 1:50)g, anti-caspase 3 (ab4051, 1:200)g and mouse
monoclonal anti-Ki67 (M7240, 1:20)n respectively. Immunolabelling
was achieved with a high-sensitive horseradish rabbit diaminobenzidine
kit with blocking of endogenous peroxidase (Envision DAB+ kit)o in an
autoimmunostainer (Cytomation S/N S38-7410-01)m. Positive staining was
confirmed on microscopy, and the area percentages of three randomly
photographed areas (at 2009 magnification) were calculated per section
with the use of LAS V4.1 softwarep [16].
Data analysis
All statistical analyses were performed using SAS statistical analysis
software version 9.3q . The treatment groups were compared at baseline
for sex using the Fisher’s exact test and for age and fetlock circumference
using the Wilcoxon rank-sum test.
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Fig 2: The evolution of the a) American Association of Equine Practitioners (AAEP) lameness scores and b) the response to flexion scores over the entire study period of
11 weeks for the horses treated with the placebo control product (CP) and the investigational veterinary product (IVP). The number of horses per score category is
displayed per time point of evaluation. W, week. *Significant difference between the two treatment groups for that time point of evaluation with P<0.05.
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Data of the joint assessment, visual lameness examination, response to
flexion, viscosity of synovial fluid, macroscopic and histological evaluation
were compared between the treatment groups with the Cochran–Mantel–
Haenszel test. Data of the joint circumference measurements, inertial
sensor analysis, pressure plate analysis, biomarker analysis, synovial fluid
cell counts, Alcian blue stain and immunohistochemistry were compared
between the treatment groups, using the Wilcoxon signed-rank test. A
Fisher’s exact test was performed to evaluate the data of the radiographic
analysis (the presence or absence of radiographic changes) and the
incidence of adverse events.
Since no detailed information on the different endpoints suing this
treatment is available, an exact sample size could not be determined.
Nevertheless, based on previous studies of our group using MSCs, a
treatment success of 83% was expected, and a placebo effect of
improvement of approximately 17% [7,8]. Based on a power of 80% and an
alpha value of 0.05, this resulted in a sample size of 6 animals per
treatment group. Moreover, this sample size has shown to generate
statistical significant results in previous studies [5,17,18]. A larger sample
size was not included due to ethical considerations.
Results
Animals
No statistically significant differences were found between the treatment
groups at day 0 for sex, age, and MCP joint circumference. For six horses
(three in each treatment group), mild cartilage changes were documented
during arthroscopy for the right MCP joint consisting of a superficial wear
line, partial erosion, minor irregularity or thinner cartilage spots. The
synovium was normal in all horses.
Efficacy outcome
Lameness examination: There was no statistically significant difference in
visual lameness scores or response to flexion between the two groups
before treatment at Week 5. After treatment, AAEP scores were
significantly lower with the intervention compared with the control from
Week 7 onwards (P = 0.002; Fig 2a). In addition, response to flexion was
also significantly lower with the intervention compared with the control
from Week 6 onwards (P = 0.02 at Week 6, P = 0.001 from Weeks 7 to 11)
(Fig 2b).
There was no significant difference in average vector sums between the
treatment groups before treatment administration under any of the
circumstances (Fig 3). At Weeks 9, 10 and 11, the vector sums on the
treadmill were significantly lower in the intervention group compared with
the control group (P = 0.02) (Fig 3a). In addition, average vector sums on a
straight line after flexion were also significantly lower in the intervention
group from Week 7 until Week 10 (P = 0.040 for Week 7 and P = 0.017 for
weeks 8, 9 and 10). At Week 11, the average vector sums were lower with
the intervention than with the control (P = 0.05 for Week 11) (Fig 3d). On
the left circle and on a straight line before flexion, the average vector sums
were lower after treatment in the intervention group compared with the
control group, especially at Week 10 and 11, but these differences were
not significant (Fig 3b, c). No statistically significant differences in symmetry
indices were found at any time point between the treatment groups with
the pressure plate analysis.
Clinical assessment, joint assessment and radiographic examination:
No serious adverse events or suspected adverse drug reactions occurred
during the study.
Before treatment, there were five horses with no increase in local
temperature and one horse with a slight increase in both the treatment
groups. All horses in the intervention group reached normal local
temperature at the injection site from Week 6 until the end of study. In the
control group, all horses reached normal local temperature the day after
treatment until the end of study.
Before treatment, there were five horses with no pain on palpation and
one horse with slight pain on palpation in both the treatment groups. All
horses in both the treatment groups were without pain to palpation from
the day after the treatment until the end of study.
After surgery, there was a limited range of motion in one horse in the
intervention group at Week 2 and in one horse of the control group at
Treadmill
Left circle
*
* *
*
* *
*
CP
IVP
CP
IVP
CP
IVP
CP
IVP
60a)
b)
c)
d)
50
40
30
V
ec
to
r 
su
m
 (m
m
)
20
10
0
Before flexion
After flexion
Time point of evaluation
–10
60
50
40
30
V
ec
to
r 
su
m
 (m
m
)
V
ec
to
r 
su
m
 (m
m
)
20
10
0
–10
60
50
40
30
V
ec
to
r 
su
m
 (m
m
)
20
10
0
–10
180
160
140
120
100
80
60
40
20
0
–20
W
0
W
1
W
2
W
3
W
4
W
5
W
6
W
7
W
8
W
9
W
10
W
11
Time point of evaluation
W
0
W
1
W
2
W
3
W
4
W
5
W
6
W
7
W
8
W
9
W
10
W
11
Time point of evaluation
W
0
W
1
W
2
W
3
W
4
W
5
W
6
W
7
W
8
W
9
W
10
W
11
Time point of evaluation
W
0
W
1
W
2
W
3
W
4
W
5
W
6
W
7
W
8
W
9
W
10
W
11
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Week 3. No change in range of motion was found in any of the animals
after Week 3.
There was no significant difference in joint effusion between the groups
until Week 7. From Week 8 onwards, the joint effusion scores were
significantly decreased with the intervention compared with the control
(P = 0.005, P = 0.01, P = 0.005 and P = 0.01 for Weeks 8, 9 10 and 11
respectively) (Fig 4a). There was no significant difference in joint
circumference between the treatment groups on any study day. The
number of radiographic changes was not significantly different between
the two treatment groups.
Synovial fluid analysis: A significantly higher viscosity score was seen
in the intervention group at Week 9 (P = 0.02) and at Week 11
(P = 0.006) (Fig 4b). There was, however, no significant difference
between the treatment groups in total white blood cells, lymphocytes,
monocytes, granulocytes and total protein at any of the time points. In
addition, no significant differences were seen in IL-10, PgE2, TGF-b3, HA,
IRAP, IL-6, IFN-c, TNF-a, SAA and MMP-13 concentrations. However, at
Week 7, the GAGs concentration in the synovial fluid was significantly
lower in the intervention group compared with the control group (mean
concentration (s.d.) of 19.9 lg/mL  5.6 vs. 44.0  28.7 lg/mL
respectively P = 0.04).
Post-mortem examination: Gross examination and histology—
Significantly less wear lines were present in the intervention group
compared with the control group on gross examination (median [range]
wear line score of 0.5 [1] vs. 2 [2] for intervention and control respectively
P = 0.02) (Fig 5a). In addition, synovitis was more prominent in the control
group (median [range] of 1 [1]) than in the intervention group (median
[range] score of 0 [2]), but the difference was not statistically significant
(P = 0.061). Synovial hyperaemia however was significantly less
pronounced in the intervention group than in the control group (median
[range] score of 0 [1] vs. 1 [1] respectively P = 0.01) (Fig 5a). No statistically
significant differences were found in erosions, extent of erosions, palmar
arthrosis, covering of subchondral bone with fibrocartilage and synovial
petechiation.
Histologically, there was no significant difference between the
intervention and control groups in chondrocyte necrosis, cluster formation,
fibrillation/fissuring, focal cell loss, cellular infiltration, vascularity, intimal
hyperplasia, subintimal oedema or subintimal fibrosis. However, a
significantly higher Alcian Blue uptake, an indirect measure of the amount
of GAGs, was seen in the cartilage adjacent to the created OC fragment in
the intervention compared with the control group (P = 0.02) (Fig 5b). No
statistically significant difference was seen for the cartilage located at the
groove. There was no presence of ectopic tissue in any animal.
Immunohistochemistry—The area % of COMP in the cartilage adjacent to
the OC fragment was significantly higher in the intervention group
compared with the control group (P = 0.02) (Fig 5b). The area % of COMP
in the cartilage of the groove lesion was not statistically different between
the two treatment groups. Collagen type II area % in the cartilage adjacent
to the OC fragment and to the groove lesion was significantly higher in the
intervention group than in the control group (P = 0.02) (Fig 5b). The area %
of Ki67 and Caspase 3 were 0% in both the treatment groups.
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Discussion
After application of the OA model, horses clinically improved when they
were treated with chondrogenic-induced MSCs combined with equine
allogeneic plasma (= intervention) compared with when they were
treated with saline (= control). Indeed, a significant reduction in visual
and objective lameness was seen for the intervention group together
with a reduced joint effusion and improved viscosity of the synovial fluid,
suggesting symptom relieve by the intervention when compared with the
control treatment. Post-mortem examination revealed a gross
improvement of cartilage appearance, with a favourable local cartilage
composition in the intervention group. Therefore, our results suggest an
improvement of local cartilage health and metabolism [3]. This
improvement was also suggested by the lower concentration of GAGs in
the synovial fluid of the intervention group joints. Indeed, a higher
concentration of GAGs in synovial fluid indicates a release of GAGs from
diseased articular cartilage into the synovial fluid, as is seen in naturally
occurring OA [19,20].
The pressure plate analysis did not reveal significant differences in the
current study, probably because this analysis was performed at the end of
all examinations and horses with OA generally display less lameness after
warming up [21]. Moreover, the pressure plate analysis only allows
evaluation of a limited number of steps while the animals are trotted in a
straight line over the plate. In contrast, the evaluation of multiple strides
using the inertial sensor-based system revealed a significant treatment
effect under different circumstances.
Overall, the results observed in this study were more conclusive
compared with those of previously reported studies on MSCs for articular
cartilage repair. Wilke et al. [5] only found an initial improved cartilage
healing after application of bone marrow-derived MSCs combined with a
fibrin vehicle in induced cartilage lesions. Frisbie et al. [4] evaluated
adipose-derived stromal vascular fraction and bone marrow-derived MSCs
for treatment of OA, and reported a greater improvement during various
evaluations with bone marrow-derived MSCs compared with placebo
treatment and adipose-derived stromal vascular fraction cells, but the
observed effects did not reach statistical significance. McIlwraith et al. [6]
evaluated the use of bone marrow-derived MSCs as an addition to
microfracture to augment healing of induced cartilage lesions, and
reported higher quality repair tissue and a higher cumulative score
during arthroscopic and gross evaluation with bone marrow-derived
MSCs. However, no clinical improvement was seen in that study. Despite
the short-term evaluation in the current study, significant effects of the
intervention product were seen in the clinical, gross and histological
examination. Differences between the current study and the previous
studies mentioned could be related to differences in the stem cell
product. In contrast to studies mentioned earlier [4–6], MSCs in the
present study were chondrogenic-induced, which has been shown to
result in better cartilage adherence in explant cultures [22]. In addition, a
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treated with the investigational veterinary product (IVP) (Week 11). Full thickness wear lines (indicated with the black arrows) are visible in the CP-treated joint, but not in
the IVP joint. Synovial hyperaemia (indicated with the white arrow) was also more pronounced in the CP-treated joint compared with the IVP-treated joint. In both joints,
the dorsomedial osteochondral (OC) fragment, which was still attached to the joint capsule, was clearly visible (encircled). b) The mean area percentages (+s.e.) of
glycosaminoglycans (GAGs), cartilage oligomeric matrix protein (COMP) and collagen type II as seen during histological and immunohistochemical analysis of the articular
cartilage sampled adjacent to the OC fragment and at the level of the groove lesion of the CP- and IVP-treated horses and of the equivalent areas in the healthy sham
operated joints. *Significant difference between the treatment groups with P<0.05.
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previous study from our group has shown a higher return-to-work-rate
when using chondrogenic-induced MSCs combined with plasma
compared with native MSCs combined with plasma [8]. Moreover, the
studies of Wilke et al. [5], Frisbie et al. [4] and McIlwraith et al. [6] used
autologous stem cell preparations, while in the current study allogeneic
MSCs were used. The use of an allogeneic product allowed high
standardisation of the MSCs resulting in one uniform product for all
horses in this study.
The intervention product we used had already been tested in an earlier
target animal safety study [23]. Despite the cells being allogeneic, only a
transient and mild local inflammatory response was seen in that study
(mild increase in lameness, heat and joint effusion), which was not
significantly different from the response after a saline injection. In the
present study, again no serious adverse events or suspected adverse drug
reactions were seen. Moreover, the joint effusion and AAEP scores were
significantly lower in the intervention group from, respectively, 3 weeks
and 2 weeks after treatment administration onwards. A possible
explanation of the lack of on inflammatory response to the ciMSCs used in
the present study is that these cells are negative for MHC class II molecules
and have a very low MHC class I expression [7]. These characteristics could
possibly allow the cells to be immune evasive, since it is known that both
MHC I and MHC II expression on MSCs can induce an immune response in
MHC-mismatched individuals [24,25].
In the current study, an experimental model was used to obtain
standardised circumstances. However, only the short-term effects of the
intervention product were tested (6 weeks), whereas naturally occurring
OA inherently presents more variability in the stage of the disease, the
speed of progression and the innate healing response of the individual
patient. Moreover, multiple statistical tests were performed, increasing the
risk of type 1 error. Therefore, the results of this experimental study should
be confirmed in a field trail on a large number of animals with naturally
occurring disease.
Conclusion
Equine allogeneic ciMSCs combined with EAP resulted in a significantly
reduced lameness and joint effusion compared with a placebo treatment
after a single intra-articular injection in MCP joints with experimentally
induced OA. In addition, a significantly improved synovial fluid viscosity,
reduced number and/or severity of wear lines, and a decreased synovial
hyperaemia was noted. Equine allogeneic ciMSCs combined with EAP also
improved local cartilage composition by significantly increasing the amount
of GAGs, COMP and collagen type II compared with saline-treated control
joints. Therefore, equine allogeneic ciMSCs combined with EAP could
potentially be a promising treatment of OA in horses.
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